Accès gratuit
Med Sci (Paris)
Volume 19, Numéro 11, Novembre 2003
Page(s) 1101 - 1110
Section M/S Revues
Publié en ligne 15 novembre 2003
  1. Marceau F, Bachvarov DR. Kinin receptors. Clin Rev Allergy Immunol 1998; 16: 385–401.
  2. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2001; 429: 161–76.
  3. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1–80.
  4. Couture R, Lindsey CJ. Brain kallikrein-kinin system: from receptors to neuronal pathways and physiological functions. In: Quirion R, Björklund A, Hökfelt T, eds. Handbook of chemical neuroanatomy: peptide receptors, part I. Amsterdam: Elsevier, 2000; 16: 241–300.
  5. Décarie A, Raymond P, Gervais N, Couture R, Adam A. Serum interspecies differences in metabolic pathways of bradykinin and (desArg9) BK: influence of enalaprilat. Am J Physiol 1996; 271: H1340–7.
  6. Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol 2000; 278: H1069–74.
  7. Regoli D, Nsa Allogho S, Rizzi A, Gobeil FJ. Bradykinin receptors and their antagonists. Eur J Pharmacol 1998; 348: 1–10.
  8. Regoli D, Rizzi A, Perron SI, Gobeil F. Classification of kinin receptors. Biol Chem 2001; 382: 31–5.
  9. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998; 50: 357–86.
  10. Velarde V, Ullian ME, Morinelli TA, Mayfield RK, Jaffa AA. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am J Physiol 1999; 277: C253–61.
  11. Adomeit A, Graness A, Gross S, Seedorf K, Wetzker R, Liebmann C. Bradykinin B2 receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation. Mol Cell Biol 1999; 19: 5289–97.
  12. Dray A. Kinins and their receptors in hyperalgesia. Can J Physiol Pharmacol 1997; 75: 704–12.
  13. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25–49.
  14. Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA. Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats. Hypertension 2001; 37: 121–8.
  15. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension. Circ Res 2001; 88: 275–81.
  16. Calixto JB, Cabrini DA, Ferreira J, Campos MM. Kinins in pain and inflammation. Pain 2000; 87: 1–5.
  17. Lortie M, Regoli D, Rhaleb NE, Plante GE. The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin. Am J Physiol 1992; 262: R72–6.
  18. Nakhostine N, Ribuot C, Lamontagne D, Nadeau R, Couture R. Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol 1993; 110: 71–6.
  19. Phagoo SB, Poole S, Leeb- Lundberg LM. Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol Pharmacol 1999; 56: 325–33.
  20. Larrivée JF, Bachvarov DR, Houle F, Landry J, Huot J, Marceau F. Role of the mitogen-activated protein kinases in the expression of the kinin B1 receptors induced by tissue injury. J Immunol 1998; 160: 1419–26.
  21. Campos MM, Souza GEP, Calixto JB. In vivo B1 kinin receptor upregulation. Evidence for involvement of protein kinases and nuclear factor-κB pathways. Br J Pharmacol 1999; 127: 1851–9.
  22. Ganju P, Davis A, Patel S, Nunez X, Fox A. p38 stressactivated protein kinase inhibitor reverses bradykinin B1 receptor-mediated component of inflammatory hyperalgesia. Eur J Pharmacol 2001; 421: 191–9.
  23. Marin-Castano ME, Schanstra JP, Neau E, et al. Induction of functional bradykinin B1 receptors in normotensive rats and mice under chronic angiotensinconverting enzyme inhibitor treatment. Circulation 2002; 105: 627–32.
  24. Sabourin T, Guay K, Houle S, et al. Absence of ligandinduced regulation of kinin receptor expression in the rabbit. Br J Pharmacol 2001; 133: 1154–62.
  25. Bhoola K, Ramsaroop R, Plendl J, Cassim B, Dlamini Z, Naicker S. Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 2001; 382: 77–89.
  26. Campos MM, Souza GE, Calixto JB. Modulation of kinin B1 but not B2 receptors-mediated rat paw edema by IL-1beta and TNFalpha. Peptides 1998; 19: 1269–76.
  27. Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, Antel JP. Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol 2000; 59: 896–906.
  28. Prat A, Weinrib L, Becher B, et al. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology 1999; 53: 2087–92.
  29. Pesquero JB, Araujo RC, Heppenstall PA, et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 2000; 97: 8140–5.
  30. Ferreira J, Campos MM, Pesquero JB, Araujo RC, Bader M, Calixto JB. Evidence for the participation of kinins in Freund’s adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology 2001; 41: 1006–12.
  31. Levy D, Zochodne DW. Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain 2000; 86: 265–71.
  32. Rabinovitch A. An update on cytokines in the pathogenesis of insulindependent diabetes mellitus. Diabetes Metab Rev 1998; 14: 129–51.
  33. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappa B in vascular smooth muscle cells. Diabetes 1999; 48: 855–64.
  34. Zuccollo A, Navarro M, Catanzaro O. Effects of B1 and B2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 1996; 74: 586–9.
  35. Mage M, Pécher C, Neau, E, et al. Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular MAP-kinase activation. Can J Physiol Pharmacol 2002; 80: 328–33.
  36. Cloutier F, Couture R. Pharmacological characterization of the cardiovascular responses elicited by kinin B1 and B2 receptor agonists in the spinal cord of streptozotocin-diabetic rats. Br J Pharmacol 2000; 130: 375–85.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.